Project Details
Description
Abstract
Malaria remains a major human parasitic disease with over half a million deaths and 247 million cases every
year. The WHO approved vaccines, RTS,S/AS01 (MosquirixTM) and R21/Matrix-M target the major
Plasmodium falciparum (Pf) pre-erythrocytic stage circumsporozoite protein (CSP) antigen (Ag). They have
limited efficacy and fall short of the global Malaria Vaccine Technology Roadmap goal of developing a 75%-
effective vaccine. The mechanisms underlying both vaccines are poorly understood. There was only very
limited analysis of the cellular responses associated with RTS,S/AS01 vaccination, partially due to the lack of
sufficiently powerful high dimensional flow cytometry analyses at the time of the study. In contrast to protection
afforded by vaccines, natural immunity provides long lived, robust protection from severe disease and death
and infection is associated with minimal to no clinical symptoms. Thus, there is a pressing need to understand
the cellular immune determinants associated with clinical immunity, to inform second generation vaccines. To
gain insights into clinical immunity, we conducted a prospective study in a malaria endemic region in Malawi,
with clinically immune and clinically susceptible individuals, using high dimensional flow cytometry phenotyping
and single cell transcriptomic. We discovered in the blood of Pf-infected patients, a population of clonally
expanded memory CD4+ T cells that express a robust cytolytic signature and reacted to the Pf-derived CSP Ag
that is also the target of RTS,S/AS01 and R21 vaccines. We hypothesize that CSP-specific cytolytic memory
CD4+ T cells could represent important mediators of natural and vaccine-induced immunity against malaria by
limiting sporozoite and liver stage pre-erythrocytic infection. Here we propose to use murine models of
radiation arrested sporozoites (RAS) immunization and sporozoite mosquito infection to explore the kinetics,
differentiation requirements, functions and protective capacity of CSP-specific cytolytic CD4+ T cells during
malaria.
| Status | Active |
|---|---|
| Effective start/end date | 1/14/25 → 12/31/25 |
Funding
- National Institute of Allergy and Infectious Diseases: $244,440.00
Fingerprint
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.